1-8 of 8
Sue Chow
Close
Sort by
Journal Articles

A Phase I Study Of Nilotinib As a c-Kit Inhibitor Combined With Re-Induction Chemotherapy For Relapsed and Refractory c-Kit Positive Acute Myeloid Leukemia

Joseph M. Brandwein, MD, David Hedley, MD, Sue Chow, Karen Yee, MD, Andre C Schuh, MD, Vikas Gupta, MD, FRCP, FRCPath, Aaron Schimmer, PhD, MD, Mark D. Minden, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 3961.
https://doi.org/10.1182/blood.V122.21.3961.3961
Published: 2013
Journal Articles

The Anti-Malarial Mefloquine Demonstrates Preclinical Activity In Leukemia and Myeloma, and Is Dependent Upon Toll-Like Receptor Signaling for Its Cytotoxicity

Mahadeo A. Sukhai, PhD, Xiaoming Li, PhD, Rose Hurren, Xiaoming Wang, Skrtic Marko, B.Sc., Hong Sun, Marcela Gronda, Ayesh Seneviratne, Dilan Dissanayake, Sue Chow, Rod Bremner, PhD, David Hedley, MD, Mark D. Minden, MD, PhD, Ohashi Pamela, PhD, FRSC, Aaron Schimmer, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 290.
https://doi.org/10.1182/blood.V116.21.290.290
Published: 2010
Journal Articles

A Phase I Study of ENMD-2076 In Patients with Relapsed or Refractory Leukemia

Karen W.L. Yee, MD, Hsaio-Wei Tina Chen, Joseph Brandwein, MD, FRCPC, Sue Chow, Deborah Sanfelice, David Hedley, MD, Vikas Gupta, MD, MRCP, FRCPath, Aaron Schimmer, MD, PhD, Carolyn Fowler Sidor, MD, Graham Fletcher, Jamie Arnott, Mark Bray, Mark D. Minden, MD, PhD, Andre Schuh, MD, FRCPC
Journal: Blood
Blood (2010) 116 (21): 3307.
https://doi.org/10.1182/blood.V116.21.3307.3307
Published: 2010
Journal Articles

Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.

Joseph Brandwein, MD, David Hedley, MD, Sue Chow, Aaron D. Schimmer, MD, PhD, Karen WL Yee, Andre Schuh, MD, Vikas Gupta, Mark D. Minden, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2073.
https://doi.org/10.1182/blood.V114.22.2073.2073
Published: 2009
Journal Articles

Antileukemic Effects of the Novel Agent Elesclomol.

Sue Chow, Masazumi Nagai, Suqin He, Ronald K Blackman, PhD, James Barsoum, PhD, Vojislav Vukovic, MD, PhD, David Hedley, MD
Journal: Blood
Blood (2009) 114 (22): 2736.
https://doi.org/10.1182/blood.V114.22.2736.2736
Published: 2009
Journal Articles

Cyproheptadine displays preclinical activity in myeloma and leukemia

Xinliang Mao, Sheng-ben Liang, Rose Hurren, Marcela Gronda, Sue Chow, G. Wei Xu, Xiaoming Wang, Reza Beheshti Zavareh, Nazir Jamal, Hans Messner, David W. Hedley, Alessandro Datti, Jeff L. Wrana, Yuanxiao Zhu, Chang-xin Shi, Kyle Lee, Rodger Tiedemann, Suzanne Trudel, A. Keith Stewart, Aaron D. Schimmer
Journal: Blood
Blood (2008) 112 (3): 760–769.
https://doi.org/10.1182/blood-2008-02-142687
Published: 2008
Includes: Supplemental data
Journal Articles

Potentiated Phospho-Protein Network Profiling of Multiple Myeloma Cell Lines and Primary Patient Samples by Multi-Parameter Flow Cytometry.

Zhi Hua Li, MD, Peter Leif Bergsagel, MD, Sue Chow, David Hedley, MD, Suzanne Trudel, MD
Journal: Blood
Blood (2007) 110 (11): 1505.
https://doi.org/10.1182/blood.V110.11.1505.1505
Published: 2007
Journal Articles

A High Throughput Screen Identified Cyproheptadine That Decreases D-Type Cyclins, Arrests Cells in the G1 Phase, and Induces Apoptosis in Multiple Myeloma and Leukemia Cells.

Xinliang Mao, PhD, A. Keith Stewart, MD, Rose Hurren, BSc, Marcela Gronda, MSc, Kyle Lee, BSc, Sue Chow, BSc, Shengben Liang, PhD, Suzanne Trudel, MD, David W. Hedley, MD, PhD, Aaron D. Schimmer, Md, PhD
Journal: Blood
Blood (2007) 110 (11): 1507.
https://doi.org/10.1182/blood.V110.11.1507.1507
Published: 2007